Balmer Lawrie Investments EV/EBIT
Cos'è EV/EBIT di Balmer Lawrie Investments?
EV/EBIT di Balmer Lawrie Investments Limited è 1.12
Qual è la definizione di EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT di aziende nel Finance settore su BSE rispetto a Balmer Lawrie Investments
Cosa fa Balmer Lawrie Investments?
Balmer Lawrie Investments Limited, together with its subsidiaries, engages in industrial packaging, greases and lubricants, leather chemicals, logistic services and infrastructure, refinery and oil field, and travel and vacation services businesses in India. The company was incorporated in 2001 and is based in Kolkata, India.
Aziende con ev/ebit simili a Balmer Lawrie Investments
- Pharos plc ha EV/EBIT di 1.09
- Jindal Poly Investment and Finance ha EV/EBIT di 1.10
- Olema Pharmaceuticals ha EV/EBIT di 1.10
- Kronos Bio ha EV/EBIT di 1.11
- Harpoon Therapeutics ha EV/EBIT di 1.12
- Public Joint Stock Mining and Metallurgical Norilsk Nickel ha EV/EBIT di 1.12
- Balmer Lawrie Investments ha EV/EBIT di 1.12
- Abraxas Petroleum ha EV/EBIT di 1.13
- Antibe Therapeutics ha EV/EBIT di 1.14
- Artelo Biosciences ha EV/EBIT di 1.15
- Artelo Biosciences ha EV/EBIT di 1.15
- Artelo Biosciences ha EV/EBIT di 1.15
- Artelo Biosciences ha EV/EBIT di 1.15